Sobi Receives Health Canada Approval for EMPAVELI® (pegcetacoplan) for the Treatment of C3G and Primary IC-MPGN
EMPAVELI® (pegcetacoplan) is the first approved treatment for C3G or primary IC-MPGN for patients 12 years and older in Canada Approval supported by Phase 3 52-week VALIANT study demonstrated reduced proteinuria, stabilized kidney function and C3 deposit clearance WALTHAM, Mass., April 09, 2026 (GLOBE NEWSWIRE) — Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) announced today that […]
Original Source
Read the full article at Financialpost →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.